Exane Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Exane Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100	Closed	-$46K	–	45
2025 Q3	$46K	Buy	+100	New	+$41.8K	0.02%	27
2021 Q3	–	Sell	-206,160	Closed	-$41.6M	–	20
2021 Q2	$41.6M	Buy	206,160 +50,908	+33%	+$10.6M	9.43%	5
2021 Q1	$33.4M	Buy	+155,252	New	+$34.1M	12.83%	2
2018 Q1	–	Sell	-1,300	Closed	-$195K	–	164
2017 Q4	$195K	Buy	1,300 +397	+44%	+$58.8K	0.06%	42
2017 Q3	$137K	Buy	+903	New	+$136K	0.03%	85

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Exane Asset Management's VRTX Position: Q4 2025 in Review

Exane Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 100 shares — an estimated $46K sold.

Exane Asset Management first reported a position in VRTX in Q3 2017 and held it in 5 quarters. The position peaked at $41.6M in Q2 2021. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

Exane Asset Management reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Exane Asset Management sold 100 Vertex Pharmaceuticals shares in Q4 2025, an estimated $46K.
Exane Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2017 and held it in 5 quarters.
Exane Asset Management's Vertex Pharmaceuticals position peaked at $41.6M in Q2 2021.
1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Exane Asset Management's 13F filing for Q4 2025, filed 27 Jan 2026.